What is Kaleido Biosciences, Inc. (KLDO)?

Kaleido Biosciences, Inc. (KLDO) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of KLDO?

The current price of KLDO is $0.00. Prices are updated in real time on Stocks360.

What is KLDO's price-to-earnings (PE) ratio?

KLDO's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is KLDO's market capitalization?

KLDO's market capitalization is $4,262.00, placing it in the small-cap tier.

Kaleido Biosciences, Inc. (KLDO)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$4.26K

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-1.17

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.20

Avg Volume

N/A

Volume

1.70K

Kaleido Biosciences, Inc. (KLDO) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $4.26K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $0.00 2026-10-28 · $0.00 (+0.00%)

Earnings

Most Recent

Apr 1, 2022

EPS $-0.47 vs est. $-0.58

Beat by $0.11

Next Earnings

Nov 2, 2026

EPS estimate $-0.59

Proprietary Signals

Signal snapshot temporarily unavailable.

About Kaleido Biosciences, Inc.

Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19. The company is also advancing programs in other significant therapeutic areas, including multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and various inflammatory bowel conditions. Kaleido maintains strategic collaborations with Institute Gustave Roussy, Washington University, and Janssen. Established in 2015, its headquarters are situated in Lexington, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	0.00×
P/FCF (TTM)	-0.00×
EV / EBITDA	0.20×
EV / Sales	-15.20×
Earnings Yield	-2156904.33%
Free Cash Flow Yield	-1835358.99%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$16.78M
Net Income (TTM)	-$91.93M
Free Cash Flow (TTM)	-$75.39M
Net Debt	-$16.78M
Working Capital	$12.63M
Gross Margin	-113.59%
Operating Margin	-7940.85%
Net Margin	-8178.26%
Return on Equity	-580.57%
Return on Invested Capital	-239.53%